Biogen Inc BIIB

Morningstar Rating
Add To Portfolio
Market Closed
129.79
2.96 | 2.23%
  • Last Close
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • Investment Style
    Mid Value
  • Market Cap
  • Forward Div Yield
  • Trailing Div Yield
  • Price/Sales
    2.50
  • Price/Book
    1.46
  • Beta (5-Year)
    0.14
  • Consensus Forward P/E
    9.65
  • Trailing 12-mo Rev
    9.82

Morningstar's Analysis

Valuation Feb 13, 2025
Currency in USD
Is it the right time to buy or sell?
Fair ValueLearn Moreplay
1-Star Price
Premium
Economic Moat
Premium
5-Star Price
Premium
Capital Allocation
Premium
Biogen Earnings: Leqembi Sales Steadily Climbing
Author Photo
Jay Lee
Senior Equity Analyst
Analyst Note | by Jay Lee Updated May 02, 2025

Biogen reported 6% year-over-year growth which was aided by the timing of Spinraza (rare disease) shipments. In-market sales of Leqembi (Alzheimer's disease) were $96 million. The company lowered 2025 guidance due to an upfront payment to Stoke, but its underlying business outlook is unchanged.

Business Strategy and Outlook | by Jay Lee Updated Feb 13, 2025

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) and Idec (classic blood cancer drug Rituxan). The firm expanded its neurology portfolio beyond MS, including the blockbuster Spinraza for spinal muscu

Morningstar Fair Value Estimate
The Morningstar Fair Value Estimate guides investors to the long-term, intrinsic value of a stock, helping them see beyond the present market price.

Show me how fair value is derived (00:41)

Morningstar calculates the fair value estimate of a company based on a projection of how much cash the company will generate in the future. Morningstar analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. The analyst discounts future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

The Morningstar Fair Value Estimate is a projection/opinion and not a statement of fact. If Morningstar's base-case assumptions are true the market price will converge on Morningstar's fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in the future and is no indication of future performance.

Morningstar Equity Research Methodology

Price vs. Fair Value

Related

Morningstar Research
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility